STMN2 and frontotemporal dementia: Previous studies demonstrated a reduction of STMN2 RNA in FTD and ALS cases (Klim et al., 2019; Melamed et al., 2019; Prudencio et al., 2020) and a decrease in STMN2 immunoreactivity in motor neurons from ALS cases compared to controls (Klim et al., 2019).